Safety and immunogenicity of an HIV-1 recombinant canarypox vaccine in newborns and infants of HIV-1-infected women.

Journal Article (Journal Article)

Pediatric AIDS Clinical Trials Group protocol 326 is a study of 2 formulations of recombinant canarypox ALVAC vaccine (vCP205) against human immunodeficiency virus type 1 (HIV-1). HIV-1-exposed infants were randomized to receive 1 of 2 formulations of vCP205 or placebo at birth and 4, 8, and 12 weeks. The vaccines were safe. Lymphoproliferative responses were detected at > or =2 time points in 44%-56% of vaccinees and none of the placebo recipients. A cytotoxic T lymphocyte response on at least 1 occasion was detected in 62.5% of infants in cohort 1 (10(6.08) median tissue culture dose [TCID(50)] vaccine formulation) and 44% of infants in cohort 2 (10(6.33) TCID(50) vaccine formulation). Rare mucosal immunoglobulin A responses and no measurable vaccine-elicited serum antibodies were detected. In children, vCP205 appeared to be safe and immunogenic.

Full Text

Duke Authors

Cited Authors

  • Johnson, DC; McFarland, EJ; Muresan, P; Fenton, T; McNamara, J; Read, JS; Hawkins, E; Bouquin, PL; Estep, SG; Tomaras, GD; Vincent, CA; Rathore, M; Melvin, AJ; Gurunathan, S; Lambert, J

Published Date

  • December 15, 2005

Published In

Volume / Issue

  • 192 / 12

Start / End Page

  • 2129 - 2133

PubMed ID

  • 16288378

International Standard Serial Number (ISSN)

  • 0022-1899

Digital Object Identifier (DOI)

  • 10.1086/498163


  • eng

Conference Location

  • United States